Author: Dorron Blumberg
GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development
Posted by Dorron Blumberg | Oct 26, 2020 | SF STAT! |
October 26, 2020 – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the signing of a Patent and Biological Materials License Agreement (the “License Agreement”) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in support of GeoVax’s development of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The Patent License Agreement to GeoVax includes access to NIAID’s patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue.
Read MoreWestside Regional Receives Healthgrades 2021 Stroke Care Excellence Award and Named Top 10 Percent in Nation for Treatment of Stroke
Posted by Dorron Blumberg | Oct 26, 2020 | SF STAT! |
Health care leaders to discuss critical industry challenges and imagine a post-COVID environment
Posted by Dorron Blumberg | Oct 26, 2020 | SF STAT! |
HCA Healthcare Reports Third Quarter 2020 Results
Posted by Dorron Blumberg | Oct 26, 2020 | SF STAT! |
Recent Posts
-
-
-
-
SMH breaks ground on Venice rehab pavilionNov 8, 2026 | SF STAT!
-













